NextPharma will provide packaging for the chronic kidney disease treatment
NextPharma has been selected as Mitsubishi Pharma Europe’s outsourcing partner for the European launch of BindRen.
BindRen is an orally available non-absorbed anion exchange resin for the treatment of hyperphosphataemia in adults with chronic kidney disease who are receiving haemodialysis or peritoneal dialysis.
NextPharma will provide primary and secondary packaging for the product within the European region. BindRen has already been launched in Germany and Austria, with other countries expected to follow shortly.
‘We needed a partner with a significant European presence and we were also impressed by the packaging solutions available at NextPharma’s state-of-the-art, solids facility in Germany,’ said Toshiaki Mikuni, Vice President of Mitsubishi Pharma Europe.
‘This is an important, high-profile launch for Mitsubishi and selecting a partner who could quickly grasp our needs and add value to our goals was essential.’
Pierre Delavaud, Executive Vice President, Sales & Marketing at NextPharma added: ‘It’s a great honour and responsibility to partner with MPE on this important project. Our respective teams have worked closely these past months to develop a solution and today we can celebrate a successful result.’